Hikma Pharmaceuticals Plc Director/PDMR Shareholding
04 3월 2025 - 8:16PM
RNS Regulatory News
RNS Number : 3056Z
Hikma Pharmaceuticals Plc
04 March 2025
Hikma Pharmaceuticals PLC -
EIP Vesting
LONDON, 4 March 2025:
Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai:
HIK) ("Hikma") (LEI:
549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility
("PDMR") have received
shares as a result of the vesting or exercise of their conditional
share awards which were granted on 25 February 2022 under the 2014
Executive Incentive Plan ("EIP") Element C and on 17 March 2016
under the EIP Element B.
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities
Said
Darwazah
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Said Darwazah
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
18,420
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 18,420
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Riad
Mishlawi
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Riad Mishlawi
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive
Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals
PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares
of 10 pence each (Shares)
ID Code:
GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C and exercise of
conditional awards under the EIP Element B.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
EIP Award, Element C:
18,691
|
|
Nil
|
EIP Award, Element B:
19,890
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 38,581
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Mazen
Darwazah
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Mazen Darwazah
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Vice Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
14,844
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 14,844
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Khalid
Nabilsi
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Khalid Nabilsi
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
17,003
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 17,003
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Bassam
Kanaan
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Bassam Kanaan
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
16,472
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 16,472
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Susan
Ringdal
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Susan Ringdal
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
8,851
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 8,851
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares sold to cover tax following
the vesting of conditional awards under the EIP Element C.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£21.71
|
4,173
|
|
d)
|
Aggregated information
|
Price(s): £21.71
Volume(s): 4,173
Total(s): £90,596.87
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Hussein
Arkhagha
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Hussein Arkhagha
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Shares acquired from the vesting of
conditional awards under the EIP Element C.
All Shares were retained.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
8,675
|
|
d)
|
Aggregated information
|
Price(s): nil
Volume(s): 8,675
|
|
e)
|
Date of the transaction
|
28 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
4 March 2025
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHBBGDXSBGDGUS
Hikma Pharmaceuticals (LSE:HIK)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Hikma Pharmaceuticals (LSE:HIK)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
